These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17305644)

  • 1. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools.
    Marcovina SM; Crea F; Davignon J; Kaski JC; Koenig W; Landmesser U; Pieri PL; Schulz-Menger J; Shaw LJ; Sobesky J
    J Intern Med; 2007 Mar; 261(3):214-34. PubMed ID: 17305644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
    Zannad F; De Backer G; Graham I; Lorenz M; Mancia G; Morrow DA; Reiner Z; Koenig W; Dallongeville J; Macfadyen RJ; Ruilope LM; Wilhelmsen L;
    Fundam Clin Pharmacol; 2012 Apr; 26(2):163-74. PubMed ID: 22220636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current possibilities for detecting high risk of cardiovascular disease.
    Simon A; Mijiti W; Gariepy J; Levenson J
    Int J Cardiol; 2006 Jun; 110(2):146-52. PubMed ID: 16343662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis.
    Koenig W
    Ann Med; 2009; 41(5):332-43. PubMed ID: 19291518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular prevention: new biochemical plasmatic markers of risk].
    Camici M; Sagripanti A
    Minerva Med; 2002 Aug; 93(4):275-86. PubMed ID: 12207197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?
    Rubin C; Nolin TD; Himmelfarb J
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):506-11. PubMed ID: 18089962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth-differentiation factor-15 in heart failure.
    Kempf T; Wollert KC
    Heart Fail Clin; 2009 Oct; 5(4):537-47. PubMed ID: 19631178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular continuum refined: A hypothesis.
    Volpe M; Camm J; Coca A; Unger T
    Blood Press; 2010 Oct; 19(5):273-7. PubMed ID: 20446877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases.
    Battistoni A; Rubattu S; Volpe M
    Int J Cardiol; 2012 May; 157(2):160-8. PubMed ID: 21763018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
    Carlquist JF; Muhlestein JB; Anderson JL
    Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of coronary artery disease. Role of noninvasive imaging].
    Knez A
    Herz; 2007 Aug; 32(5):395-403. PubMed ID: 17687529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].
    Pede S; Lombardo M
    Ital Heart J Suppl; 2001 Apr; 2(4):356-8. PubMed ID: 19397006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What are the biomarkers of atherosclerosis and cardiovascular risk?].
    Riesen WF
    Rev Med Suisse; 2008 Mar; 4(148):636-8, 640-3. PubMed ID: 18459658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
    Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of cardiac disease.
    Marian AJ; Nambi V
    Expert Rev Mol Diagn; 2004 Nov; 4(6):805-20. PubMed ID: 15525223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of cardiovascular damage and dysfunction--an overview.
    Collinson PO; Gaze DC
    Heart Lung Circ; 2007; 16 Suppl 3():S71-82. PubMed ID: 17618829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mainstream hypothesis that LDL cholesterol drives atherosclerosis may have been falsified by non-invasive imaging of coronary artery plaque burden and progression.
    Ware WR
    Med Hypotheses; 2009 Oct; 73(4):596-600. PubMed ID: 19560285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational biology for cardiovascular biomarker discovery.
    Azuaje F; Devaux Y; Wagner D
    Brief Bioinform; 2009 Jul; 10(4):367-77. PubMed ID: 19276200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of sepsis.
    Marshall JC; Reinhart K;
    Crit Care Med; 2009 Jul; 37(7):2290-8. PubMed ID: 19487943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.